Influenza A H1N1 Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled Dose Ranging Study Evaluating Safety, Pharmacokinetics and Clinical Benefit of FLU-IGIV in Hospitalized Patients With Serious Influenza A Infection
Verified date | March 2024 |
Source | Emergent BioSolutions |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Influenza, or the flu, is an infectious respiratory disease that can range in severity from mild to severe to even death. This study aims to evaluate a treatment for people who are hospitalized with the flu. The study is looking to see if antibodies collected from people who have recovered from the seasonal flu or who have had the seasonal flu shot can be used safely as a study drug to treat hospitalized patients with severe flu infections. Also, this study will help to find the right dose for this study drug for treatment of severe flu in hospitalized patients. Overall, this study will evaluate if the hospitalized patients receiving standard of care along with the study drug get better more quickly than those treated with standard of care and placebo. The study drug that contains antibodies against the flu is called anti-influenza immunoglobulin intravenous (FLU-IGIV).
Status | Completed |
Enrollment | 65 |
Est. completion date | June 17, 2019 |
Est. primary completion date | June 17, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Provision of voluntary informed consent in writing by patient, or legally authorized representative. - Age = 18 years of age. - Locally determined positive influenza A infection (Rapid Antigen (Ag) Test or PCR) from a specimen obtained within 2 days prior to randomization. - Onset of symptoms = 6 days before randomization, defined as when the patient first experienced at least one respiratory symptom or fever. - Hospitalized (or in observation unit) with influenza, with anticipated hospitalization for more than 24 hours and will be/already are receiving antiviral SOC. - Experiencing = 1 respiratory symptom (ex. cough, sore throat, nasal congestion) and = 1 constitutional symptom (ex. headache, myalgia, feverishness or fatigue). - For women of child-bearing potential: willingness to abstain from sexual intercourse or use at least 1 form of hormonal or barrier contraception through Day 60 of the study. - Willingness to have blood and respiratory samples obtained and stored. - National Early Warning Score (NEW score) = 3 at screening. Exclusion Criteria: - Use of any investigational product within the past 30 days prior to screening. - History of hypersensitivity to blood or plasma products (as judged by the site investigator). - History of allergy to latex or rubber. - Known medical history of IgA deficiency. - Pregnancy or lactation. - Medical conditions for which receipt of a 500 mL volume of intravenous fluid may be dangerous to the patient (e.g. decompensated congestive heart failure), based on investigator's medical opinion with careful consideration of lab results. - Liver function: liver function test (LFT) > 2.5 times upper limit of normal (ULN). - Renal Function: glomerular filtration rate (GFR) < 60 mL/min/1.73 m2 (age and sex adjusted). - A pre-existing condition or use of a medication that, in the opinion of the site investigator, may place the individual at a substantially increased risk of thrombosis (e.g. cryoglobulinemia, severe refractory hypertriglyceridemia, or clinically significant monoclonal gammopathy). - An opinion of the investigator that it would be unwise to allow participation of the patient in the study (the reason for exclusion of the patient must be documented). - Receiving extracorporeal membrane oxygenation (ECMO). - Anticipated life expectancy of < 90 days. - Confirmed bacterial pneumonia or any concurrent respiratory viral infection that is not influenza A (ex. respiratory syncytial virus (RSV) infection). |
Country | Name | City | State |
---|---|---|---|
Canada | Foothills Medical Centre | Calgary | Alberta |
Canada | CISSS BSL/Hopital Regional de Rimouski | Rimouski | Quebec |
Canada | Ciusss McQ | Trois-Rivières | Quebec |
Canada | Grace Hospital | Winnipeg | Manitoba |
Canada | Health Sciences Center | Winnipeg | Manitoba |
Canada | St. Boniface Hospital | Winnipeg | Manitoba |
Puerto Rico | Mayaguez Medical Center | Mayagüez | |
Puerto Rico | San Cristobal Hospital | Ponce | |
Spain | Hospital Clinic of Barcelona | Barcelona | |
Spain | Hospital del Mar | Barcelona | |
Spain | Hospital Universitari Mutua Terrassa | Barcelona | |
Spain | Reina Sofia University Hospital | Córdoba | |
Spain | Hospital Universitari de Tarragona Joan XXIII | Tarragona | |
United States | Atlanta Institute for Medical Research Inc. | Atlanta | Georgia |
United States | Northside Hospital | Atlanta | Georgia |
United States | Augusta University | Augusta | Georgia |
United States | John Hopkins Hospital | Baltimore | Maryland |
United States | St Luke's University Health Network | Bethlehem | Pennsylvania |
United States | University of Alabama at Birmingham | Birmingham | Alabama |
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | Montefiore Medical Center | Bronx | New York |
United States | University of North Carolina | Chapel Hill | North Carolina |
United States | Northwestern University | Chicago | Illinois |
United States | University of Chicago | Chicago | Illinois |
United States | Baylor University Medical Center | Dallas | Texas |
United States | UT Southwestern Medical Center | Dallas | Texas |
United States | Premier Health Miami Valley Hospital | Dayton | Ohio |
United States | Denver public Health | Denver | Colorado |
United States | Wayne State University/Detroit Receiving Hospital | Detroit | Michigan |
United States | Wayne State University/Sinai Grace Hospital | Detroit | Michigan |
United States | Pulmonlx LLC Pulmonary & Critical Care Medicine | Greensboro | North Carolina |
United States | Baylor College of Medicine | Houston | Texas |
United States | Michael E. DeBakey VA Medical Center | Houston | Texas |
United States | University of Iowa | Iowa City | Iowa |
United States | University of Kansas medical Center | Kansas City | Kansas |
United States | University Medical Center of Southern Nevada | Las Vegas | Nevada |
United States | Baptist Health Center for Clinical Research | Little Rock | Arkansas |
United States | Yale University School of Medicine | New Haven | Connecticut |
United States | Christiana Care Health Systems | Newark | Delaware |
United States | University of Oklahoma | Oklahoma City | Oklahoma |
United States | University of Nebraska Medical Center | Omaha | Nebraska |
United States | University of California, Irvine Emergency Medicine | Orange | California |
United States | Einstein Medical Center | Philadelphia | Pennsylvania |
United States | Allegheny General Hospital | Pittsburgh | Pennsylvania |
United States | Regional Health | Rapid City | South Dakota |
United States | Carilion Medical Center | Roanoke | Virginia |
United States | Mayo Clinic | Rochester | Minnesota |
United States | Washington University | Saint Louis | Missouri |
United States | University of Utah HealthCare | Salt Lake City | Utah |
United States | UT Health San Antonio | San Antonio | Texas |
United States | HonorHealth | Scottsdale | Arizona |
United States | Providence-Providence Park Hospital, Southfield | Southfield | Michigan |
United States | MultiCare Institute for Research & Innovation | Tacoma | Washington |
United States | Reading Hospital | West Reading | Pennsylvania |
United States | University of Massachusetts Memorial Medical Center | Worcester | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Emergent BioSolutions |
United States, Canada, Puerto Rico, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Frequency Counts and Percentage of Subjects With Adverse Events | Frequency counts and percentage of subjects with Adverse Events by severity | Measured through Day 60 | |
Primary | Area Under the Plasma Concentration Curve [AUC] From Time 0 to 48 Hours Post-dose by Hemagglutinin Inhibition Assay | Levels of anti-influenza A antibodies circulating in blood over time. We initially intended to look at this variable through Day 8, however, potential native antibody level changes and sparse sampling confounded results from 0 to 48 hours post-dose from PK samples collected from Baseline Day 1 pre-dose (time 0), Day 1 post-dose, Day 2 and Day 3 (if continued hospitalization), and Day 8. For AUC from time 0 to 48 hours, subjects who did not have a sample collected within +/-10% of 48 hours post-dose had this parameter set to missing, which is why the number of subjects who contributed data for this outcome measure is lower than the overall number of subjects analyzed. | Measured through 48 Hours post-dose | |
Primary | Maximum Plasma Concentration [Cmax] Reported as a Titer for Hemagglutinin Inhibition Assay | Maximum observed concentration (reported as a titer) of anti-influenza A antibodies measured from Day 1 pre-dose (time 0) through Day 8 post-dose from PK samples collected from Baseline Day 1 pre-dose (time 0), Day 1 post-dose, Day 2 and Day 3 (if continued hospitalization), and Day 8. | Measured through Day 8 post-dose | |
Primary | Time Cmax is Observed [Tmax] by Hemagglutinin Inhibition Assay | Time that anti-influenza A antibodies are at maximum concentration from Day 1 pre-dose (time 0) through Day 8 post-dose from PK samples collected from Baseline Day 1 pre-dose (time 0), Day 1 post-dose, Day 2 and Day 3 (if continued hospitalization), and Day 8.
The rate of study drug elimination and dependent parameters were not accurately estimable due to rising or sustained levels of anti-influenza A antibodies, this includes First Order Terminal Elimination Rate Constant [Kel], Plasma Clearance [Cl] and Total Volume of Distribution [Vz]. |
Measured through Day 8 post-dose | |
Secondary | Ordinal Scale Subject Distribution Reflecting Clinical Status | Score (physician-assessed): 1=death; 2=hospitalization in the intensive care unit (ICU); 3=non-ICU hospitalization requiring supplemental oxygen; 4=non-ICU hospitalization not requiring supplemental oxygen; 5=no longer hospitalized but unable to resume normal activities; 6=no longer hospitalized with full resumption of normal activities. A higher score reflects improved clinical status. Not all ITT subjects had ordinal scale data available at Day 8 post-dose which explains why the overall number of participants analyzed is not consistent with the overall number of subjects included at baseline. For subjects who were discharged with unknown ordinal score the more conservative of two relevant discharged categories was imputed. | At Day 8 post-dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05572450 -
Dose, Safety, and Pathogenicity of a New Influenza H1N1 Challenge Strain
|
N/A | |
Completed |
NCT06385821 -
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
|
Phase 3 | |
Active, not recruiting |
NCT04850898 -
Study of SAB-176 in Healthy Adult Participants
|
Phase 2 | |
Completed |
NCT03743688 -
Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults
|
||
Recruiting |
NCT04499378 -
Tomographic Findings in COVID-19 and Influenza H1N1
|